Esomeprazole in the treatment of duodenal ulcer under various regimens of antichelicobacter therapy

Terapevticheskii Arkhiv

Volumn 75, Issue 2, 2003, Pages 23-26

  Maev, I V ^a   Kurilo, A E ^a   Vyuchnova, E S ^a   Schekina, M I ^a  

^a NONE

Author keywords

Duodenal ulcer; Eradication; Esomeprazole; Helicobacter pylori; Nexium; Treatment

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; OMEPRAZOLE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; ENZYME INHIBITOR;

ARTICLE; BIOLOGICAL MONITORING; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; DUODENUM ULCER; EPITHELIZATION; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; RANDOMIZATION; SIDE EFFECT; STOMACH PH; STOMACH SECRETION; TIME; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HELICOBACTER INFECTION; MALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; DUODENAL ULCER; ENZYME INHIBITORS; FEMALE; HELICOBACTER INFECTIONS; HUMANS; MALE; OMEPRAZOLE;

EID: 0038113431     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Abelo A., Andersson T., Antonsson M. et al. Stereoselectivc metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab. Dispos. 2000; 28: 966-972.
2. Andersson T., Rohss K., Hassan-Alin M. et al. Pharmacokineticks (PK) and dose-response relationship of esomeprazole (E). Gastoenterology 2000; 118(4, suppl. 2): 210, abstr. 5550.
3. Andersson T., Bredberg E., Sunzel M. et al. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (POA) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O). Ibid. 1210, abstr. 5551.
4. Lind T., Rydberg L., Kyleback A. et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2000; 14(7): 861-867.
5. Rohss K., Claar-Nilsson C., Rydholm H. Esomeprazole 40 mg provides more effective acid control than lanzoprazole 30 mg. Gastroenterology 2000; 118: A20.
6. Rohss K., Wilder-Smith C. H., Claar-Nilsson C. et al. Esomeprazole 40 mg provides more effective acid control than standard doses of all proton pump inhibitors [abstract]. Ibid. 2001; 120: abstr. 2140.
7. Wilder-Smith C., Rohss K., Lundin C. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Ibid. 2000; 118: A22.
8. Veldhuyzen van Zanten S. J. O., Lauritsen K., Delchier J.-C. et al. 7-day triple therapy with esomeprazole, amoxicillin and clarithromycin for H. pylori (HP) eradication in duodenal ulcer (DU) disease [abstract and poster presented at Digestive Disease Week; 2000 May 21-24; San Diego, California]. Ibid. A503.
9. Tulassay Z., Kryszewski A., Ditz P et al. 7-day treatment esomeprazole-based triple therapy eradicates H. pylori (HP) and heals patient with DU disease [abstract and poster presented at Digestive Disease Week; 2000 May 21-24: San Diego, California]. Ibid. A502.
10. Laine L., Fennerty B., Osato M. et al. Esomeprazole-based Helicobacter-pylori eradication therapy and effect of antibiotic resistance: Results of three US multicenter, double-blind trials. Ant. J. Gastroenterol. 2000; 95(12): 3393-3398.
11. Karhilas P. J., Folk G. W., Johnson D. A. et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment. Pharmacol. Ther. 2000. 14: 1249-1258.
12. Richter J. E., Karhilas P. J., Hwang G. et al. Esomeprazole is superior for omeprazole for healing of erosive esophagitis (EE) in GERD patients [abstract and poster presented at Digestive Disease Week; 2000 May 21-24: San Diego. California]. Gastroenterology 2000; 118: A20.
13. Talley N. J., Venables T. L., Green J. B. R. et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative GERD: a placebo-controlled trial of on-demand therapy for 6 months [abstract]. Ibid. A658.
14. Talley N. J., Lauritsen K., Tunturi-Hihnala H. et al. Esomeprazole 20 mg maitains symptom control in endoscopy-negative GERD: a randomized placebo-controlled trial of on-demand therapy for 6 month [abstract and poster presented at Digestive Disease Week; 2000 May 21-24: San Diego, California]. Ibid. A21.